The combined inhibition of the TIGIT and PD-1/PD-L1 signaling pathways can also lead to the synergistic enhancement of the proliferation and function of anti-tumor CD8+ T cells, thus boosting anti-tumor efficacy and ultimately improving overall patient survival. Here, CD8A is linked to neoplasm.